Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)

American Heart Journal

Volumn 149, Issue 3, 2005, Pages 548-557

  Maggioni, Aldo P ^a   Latini, Roberto ^b   Carson, Peter E ^d   Singh, Steven N ^d   Barlera, Simona ^b   Glazer, Robert ^e   Masson, Serge ^b   Cerè, Elisabetta ^c   Tognoni, Gianni ^b   Cohn, Jay N ^f  

^a ANMCO RESEARCH CENTER   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Ospedale di Bentivoglio   (Italy)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PLACEBO; VALSARTAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINUS RHYTHM; TREATMENT OUTCOME;

EID: 17844369714     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.09.033     Document Type: Article

References (32)

1. W.B. Kannel, R.D. Abbott, and D.D. Savage Epidemiologic features of atrial fibrillation: the Framingham study N. Engl. J. Med. 306 1982 1018 1022
2. G.E. Kachiadakis, N.E. Igoumenidis, and M.E. Marketou Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation Am. J. Cardiol. 81 1998 995 998
3. M.R. Southworth, D. Zarembski, and M. Viana Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation Am. J. Cardiol. 83 1999 1629 1632
4. V. Kuhlkamp, A. Schirdewan, and K. Stangl Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. A randomized, double-blind, placebo-controlled study J. Am. Coll. Cardiol. 36 2000 139 146
5. E.L.C. Pritchett, R.L. Page, and S.J. Connolly Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response J. Am. Coll. Cardiol. 36 2000 794 802
6. D. Roy, M. Talajic, P. Dorian for the Canadian Trial of Atrial Fibrillation Investigators Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators N. Engl. J. Med. 342 2000 913 920
7. M.C. Wijffels, C.J. Kirchhof, and R. Dorland Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats Circulation 92 1995 1954 1968
8. S. Nattel, and D. Li Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation Circ. Res. 87 2000 440 447
9. E.G. Daoud, P. Marcovitz, and B.P. Knight Short-term effect of atrial fibrillation on atrial contractile function in humans Circulation 99 1999 3024 3027
10. S. Nattel New ideas about atrial fibrillation 50 years on Nature 415 2002 219 226
11. K. Kumagai, H. Nakashima, and H. Urata Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation J. Am. Coll. Cardiol. 41 2003 2197 2204
12. D. Li, K. Shinagawa, and P. Li Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure Circulation 104 2001 2608 2614
13. H. Nakashima, K. Kumagai, and H. Urata Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation Circulation 101 2000 2612 2617
14. O.D. Pedersen, H. Bagger, and L. Kober Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 100 1999 376 380
15. E. Vermes, J.C. Tardif, and M.G. Bourassa Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies of Left Ventricular Dysfunction (SOLVD) Trials Circulation 107 2003 2926 2931
16. A.H. Madrid, M.G. Bueno, and J.M. Rebollo Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study Circulation 106 2002 331 336
17. J.N. Cohn, G. Tognoni, and R.D. Glazer Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure J. Card. Fail. 5 1999 155 160
18. J.N. Cohn, G. Tognoni for the Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N. Engl. J. Med. 345 2001 1667 1675
19. D.R. Cox, and D. Oakes Analysis of survival data 1984 Chapman and Hall London
20. N. Mantel, and D.P. Byar Evaluation of response-time data involving transient states: an illustration using heart transplant data J. Am. Stat. Assoc. 69 1974 81 86
21. J.J.V. McMurray, J. Östergren, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added Trial Lancet 362 2003 767 771
22. C. Granger, J.J.V. McMurray, and S. Yusuf Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin converting-enzyme inhibitors: the CHARM-Alternative Trial Lancet 362 2003 772 776
23. M.A. Pfeffer, K. Swedberg, and C.B. Granger Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766
24. B. Dalhof, R.B. Devereux, and S.E. Kjeldson Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
25. P.A. Poole-Wilson, K. Swedberg, and J.G.F. Cleland Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 2003 7 13
26. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
27. A.E. Tuinenburg, D.J. Van Veldhuisen, and F. Boomsma Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm Am. J. Cardiol. 81 1998 1207 1210
28. S. Masson, M. Gorini, and M. Salio Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry Ital. Heart J. 1 2000 282 288
29. H.U. Klein, and A. Goette Blockade of atrial angiotensin II type 1 receptors. A novel antiarrhythmic strategy to prevent atrial fibrillation? J. Am. Coll. Cardiol. 41 2003 2205 2206
30. M. Pozzoli, G. Cioffi, and E. Traversi Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm J. Am. Coll. Cardiol. 32 1998 197 204
31. D.L. Dries, D.V. Exner, and B.J. Gersh Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction J. Am. Coll. Cardiol. 32 1998 695 703
32. J. Mathew, S. Hunsberger, and J. Fleg Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure Chest 118 2000 914 922